Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming 12th Annual UBS Global Life Sciences Conference on September 22, 2010 at 3:30 pm ET. The conference is being held at the Grand Hyatt in New York City.
Mr. Moch will discuss the company’s antiviral pipeline and technology assets, including CMX001, a broad spectrum antiviral in clinical development for the treatment of double-stranded DNA viruses such as cytomegalovirus, adenovirus, BK virus, JC virus, Epstein-Barr virus and herpes simplex virus; and CMX157, being developed as a potential once-weekly nucleoside analogue against HIV infections.
Source: Chimerix, Inc